Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

10.27
-0.5200-4.82%
Post-market: 10.270.00000.00%19:48 EDT
Volume:740.85K
Turnover:7.64M
Market Cap:895.10M
PE:-4.82
High:10.77
Open:10.69
Low:10.19
Close:10.79
52wk High:36.26
52wk Low:5.36
Shares:87.16M
Float Shares:71.89M
Volume Ratio:1.18
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1289
EPS(LYR):-1.8700
ROE:-52.74%
ROA:-31.82%
PB:2.08
PE(LYR):-5.49

Loading ...

Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Aug 20

Olema Oncology appoints Jason O’Byrne as CFO

TIPRANKS
·
Aug 17

Olema Pharmaceuticals is Maintained at Overweight by JP Morgan

Dow Jones
·
Aug 13

Olema Pharmaceuticals Names Jason O’Byrne CFO

Reuters
·
Aug 13

Olema Oncology Appoints Jason O’byrne as Chief Financial Officer

THOMSON REUTERS
·
Aug 13

Press Release: Olema Oncology Appoints Jason O'Byrne as Chief Financial Officer

Dow Jones
·
Aug 13

Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs

Reuters
·
Aug 13

Sutro Biopharma Q2 Revenue Misses Estimates, Posts Wider Loss

Reuters
·
Aug 12

Oncology Firm Immunome's Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 12

Sellas Life Sciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 12

Erasca Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 12

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Benzinga Earnings
·
Aug 12

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Damora Therapeutics (DMRA)

TIPRANKS
·
Aug 11

Imunon Q2 Net Loss Widens Slightly as R&D Costs Rise

Reuters
·
Aug 11

Tyler Van Buren Reiterates Buy on Olema, Citing Palazestrant’s Late-Stage Differentiation and Multiple Value-Creating Catalysts

TIPRANKS
·
Aug 11

Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained

TIPRANKS
·
Aug 11

Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss

MT Newswires Live
·
Aug 11

DiaMedica Q2 Net Loss Widen Less than Expected

Reuters
·
Aug 11

Perspective Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 11

Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029

Reuters
·
Aug 11